For a lark

FRAMINGHAM (02/27/2004) - Genaissance Pharmaceuticals Inc. will acquire Houston-based genomic services company Lark Technologies Inc. in an all-stock transaction valued at approximately US$19.9 million. Carl Balezentis, president and CEO of Lark, will join Genaissance as senior vice president and remain president of Lark Technologies. The transaction is expected to close in the first half of this year.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about Genaissance Pharmaceuticals

Show Comments